中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (1): 51-54.doi: 10.12144/zgmfskin202501051

• 临床研究 • 上一篇    下一篇

托法替布治疗原发性皮肤淀粉样变一例并文献复习

袁瑞清1,2，周桂芝1,2，刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2025-01-15 发布日期:2024-12-23

Tofacitinib in the treatment of primary cutaneous amyloidosis: a case report and literature review

YUAN Ruiqing1,2, ZHOU Guizhi1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-01-15 Published:2024-12-23

PDF (PC)

77

摘要： 原发性皮肤淀粉样变是一种慢性瘙痒性疾病，目前缺乏标准的治疗方案，传统疗法如抗组胺药、沙利度胺和局部糖皮质激素等疗效欠佳。有研究认为纠正瘙痒-搔抓-瘙痒的恶性循环是治疗原发性皮肤淀粉样变的关键，托法替布是一种口服泛JAK抑制剂，可显著降低特应性皮炎小鼠模型的抓挠行为和IL-4和IL-31的表达，本文报道一例托法替布治疗原发性皮肤淀粉样变并复习相关文献。

关键词: 托法替布, 原发性皮肤淀粉样变, JAK抑制剂

Abstract: Primary cutaneous amyloidosis is a chronic itching disease. At present, there is a lack of standard treatment plans for this disease, and traditional therapies such as antihistamines, thalidomide, and local glucocorticoids have poor therapeutic effects. Studies have suggested that correcting the itch-scratch-itch cycle is the key to treating primary cutaneous amyloidosis. Tofacitinib is an oral JAK inhibitor, it can significantly reduce the scratching behavior and the expression of IL-4 and IL-31 in a mouse model of atopic dermatitis. A case of primary skin amyloidosis treated with tofacitinib is reported and the related articles are reviewed.

Key words: tofacitinib, primary cutaneous amyloidosis, JAK inhibitor